NCT05938179View on ClinicalTrials.gov

A Study of HS-10353 in Adult Participants With Major Depressive Disorder

PHASE2UnknownINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

August 31, 2023

Primary Completion Date

November 1, 2024

Study Completion Date

April 30, 2025

Conditions
Major Depressive Disorder (MDD)
Interventions
DRUG

HS-10353 30mg oral capsules

HS-10353 30mg oral capsules

DRUG

HS-10353 50mg oral capsules

HS-10353 50mg oral capsules

DRUG

Placebo for HS-10353 30mg capsules

Placebo for HS-10353 30mg capsules

DRUG

Placebo for HS-10353 50mg capsules

Placebo for HS-10353 50mg capsules

Sponsors
All Listed Sponsors
lead

Jiangsu Hansoh Pharmaceutical Co., Ltd.

INDUSTRY